^
BIOMARKER:

PLK1 overexpression

i
Other names: PLK1, Polo Like Kinase 1, Serine/Threonine-Protein Kinase PLK1, Serine/Threonine-Protein Kinase 13, Polo-Like Kinase 1, STPK13, PLK-1, Cell Cycle Regulated Protein Kinase, Polo-Like Kinase (Drosophila), Polo (Drosophia)-Like Kinase
Entrez ID:
Related biomarkers:
9d
However, the inhibition of FUNDC1 abolished the positive effect of PLK1 on H9c2 cells mentioned above. In conclusion, PLK1 alleviated the ischemia reperfusion induced myocardial damage by inducing the mitophagy in a p-AMPK/FUNDC1 signaling dependent pathway.
Preclinical • Journal
|
PLK1 (Polo Like Kinase 1)
|
PLK1 overexpression • AMPK expression
17d
Global methylation survival analysis showed that prognostic value of PLK1/2/4 methylation remained the same significant trend between two lung cancer subtypes, whereas prognostic value of PLK3 methylation lacked consistency. Taken together, these results provided instructive insights into a comprehensive evaluation for advanced therapeutic strategy based on epigenetic evidences.
Journal
|
TP53 (Tumor protein P53) • PLK1 (Polo Like Kinase 1) • PLK2 (Polo Like Kinase 2)
|
TP53 mutation • PLK1 overexpression • PLK2 underexpression
4ms
High Plk1 expression conferred a resistant phenotype of ccRCC to targeted therapeutics such as sunitinib, in vitro, in vivo, and in metastatic ccRCC patients. Importantly, high Plk1 expression was defined in a subpopulation of ccRCC patients that are refractory to current therapies. Hence, we propose a therapeutic paradigm for improving outcomes of ccRCC patients.
Journal
|
PLK1 (Polo Like Kinase 1)
|
PLK1 overexpression
|
Sutent (sunitinib)
6ms
Here, we provided sufficient evidence of PLK1 overexpression in cervical cancer. The overexpression of PLK1 in cervical cancer and the contributory effect of it on clinical progression indicated the hopeful prospect of PLK1 as a biomarker for cervical cancer.
Journal
|
EGFR (Epidermal growth factor receptor)
|
PLK1 overexpression
6ms
On the other hand, we discuss recent evidence that unveils synthetic lethality induction by PLK1 inhibition in BRCA1-deficient cancers cells. This previously unforeseen therapeutic link between PLK1 and BRCA1 is promising because it defines novel therapeutic opportunities for PLK1i not only for breast cancer (i.e. TNBCs with BRCA1 deficiencies), but also for other types of cancers with BRCA1-deficiencies, such as pancreatic and prostate cancers.
Review • Journal • BRCA Biomarker
|
BRCA1 (Breast cancer 1, early onset)
|
PLK1 overexpression
VERI is free for non-commercial use, no login needed.
Content on this site is for research purposes only and is not intended  to be a substitute for medical advice.
For commercial access, including additional premium features, please contact us.
By using VERI, you are agreeing to our